Evaluation of the effect of obesity on voriconazole serum concentrations

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 12, 2012, Pages 2957-2962

  Koselke, Elizabeth ^a   Kraft, Shawna ^a   Smith, Jeannina ^b   Nagel, Jerod ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Adjusted body weight; Dosing; Ideal body weight; Toxicity

Indexed keywords

VORICONAZOLE;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG SCREENING; FEMALE; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; OBESITY; RETROSPECTIVE STUDY;

ADULT; AGED; ANTIFUNGAL AGENTS; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; OBESITY; PYRIMIDINES; RETROSPECTIVE STUDIES; SERUM; TIME FACTORS; TRIAZOLES;

EID: 84869468615     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks312     Document Type: Article

References (16)

1. WHO. Obesity and Overweight, Fact Sheet 311. 2011. http://www.who.int/mediacentre/factsheets/fs311/en/ (7 January 2012, date last accessed).
2. Lewis RE. What is the 'therapeutic range' for voriconazole? Clin Infect Dis 2008; 46: 212-4.
3. Smith J, Andes D. Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations. Ther Drug Monit 2008; 30: 167-72.
4. Smith J, Safdar N, Knasinski V et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006; 50: 1570-2.
5. Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother 2009; 53: 24-34.
6. Kim SH, Yim DS, Choi SM et al. Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients. Int J Infect Dis 2011; 15: 753-8.
7. Pascual A, Calandra T, Bolay S et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46: 201-11.
8. Purkins L, Wood N, Ghahramani P et al. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother 2002; 46: 2546-53.
9. Howard A, Hoffman J, Sheth A. Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis. Ann Pharmacother 2008; 42: 1859-64.
10. Pai MP, Bearden DT. Antimicrobial dosing considerations in obese adult patients. Pharmacotherapy 2007; 27: 1081-91.
11. Troke PF, Hockey HP, Hope WW. Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients. Antimicrob Agents Chemother 2011; 55: 4782-8.
12. Voriconazole (Package Insert), Revised Version. New York, NY: Pfizer, 2011.
13. Miyakis S, van Hal SJ, Ray J et al. Voriconazole concentrations and outcomeof invasive fungal infections. Clin Microbiol Infect 2010; 16: 927-33.
14. Pai MP, Lodise TP. Steady-state plasma pharmacokinetics of oral voriconazole in obese adults. Antimicrob Agents Chemother 2011; 55: 2601-5.
15. Davies-Vorbrodt S, Ito J, Dadwal S et al. Voriconazole serum levels in obese immunocompromised patients. In: Abstracts of the Fifty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2011. Abstract A1-1154. American Society for Microbiology, Washington, DC, USA.
16. Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet 2006; 45: 649-63.